Interestingly, we observed similar overall survival between the TP53-wildtype IDH1R132H subgroup and the TP53-altered IDH1R132X subgroup based on the available size of samples; however, the paramount importance of TP53 status in IDH1R132X glioma requires validation with independent cohorts. Here, TP53 is linked to central nervous system cancer.